Effect of human recombinant interleukin-33 on collagen mRNA expression in lung fibroblasts
-
1
National University of Pharmacy, Ukraine
The purpose of this study was to investigate the effect of IL-33 on the expression of collagen type I alpha 1 (COL1A1), collagen type I alpha 2 (COL1A2), and collagen type 3 alpha 1 (COL3A1) mRNA in human lung fibroblasts (HLF).
HLF were grown to confluence in RPMI-1640 medium supplemented with 10% fetal bovine serum, then cells were serum starved in media containing 0.5% dialyzed fetal bovine serum, and 24 hours later, treated with different concentrations (2 to 300 ng/ml) of recombinant human IL-33. mRNA expression levels for COL1A1, COL1A2, and COL3A1 were measured by real-time RT-PCR.
Stimulation of the lung fibroblasts with IL-33 led to a dose-dependent increase in the steady state level of COL3A1 mRNA, but not in COL1A1, and COL1A2 mRNA. The maximum effect of IL-33 on COL3A1 mRNA expression (4.3 fold increase, p < 0.05) was observed at 10 ng/ml. This finding suggests that IL-33 can enhance type 3 collagen gene expression, forms conditions promoting the development of fibrotic disorders.
Keywords:
interleukin-33,
lung fibroblasts,
Collagen,
mRNA expression,
fibrotic disorders
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Innate immunity
Citation:
Bocharov
A,
Filimonova
N and
Sheveleva
N
(2013). Effect of human recombinant interleukin-33 on collagen mRNA expression in lung fibroblasts.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00503
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
02 Jun 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Dr. Alexander Bocharov, National University of Pharmacy, Kharkov, Ukraine, a.a.botcharov@gmail.com